Capio Biosciences is an oncology diagnostics company that develops advanced technologies for capturing and analyzing circulating tumor cells (CTCs) from whole blood. Its proprietary CapioCyte platform offers enhanced sensitivity compared to traditional methods, serving as a research tool designed to help oncologists make informed cancer treatment decisions.
Subscribe to see Capio Biosciences, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Capio Biosciences, Inc. is a biotechnology company headquartered in Madison, United States. Its most recent funding round, Series A, raised $2.9M in December 2016. Xcout tracks 5 named people at Capio Biosciences, Inc., including Chang-Woo Lee (Chief Technology Officer).
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $2.9M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Capio Biosciences, Inc.'s closest competitors — see the full list of competitors and alternatives →
Precede Biosciences is a biotechnology company developing blood-based liquid-biopsy technologies for molecular profiling of cancer. Its tests are intended to support oncology research, precision treatment decisions, and pharmaceutical drug-development programs.
SAGA Diagnostics provides ultra-sensitive, blood-based molecular residual disease (MRD) detection and monitoring tests for cancer patients. The company's flagship platform, Pathlight, uses tumor whole-genome sequencing and personalized digital PCR assays to detect circulating tumor DNA, primarily serving clinicians and biopharmaceutical partners for early cancer detection and treatment tracking.
Resolution Bioscience develops and commercializes next-generation sequencing-based precision oncology solutions and liquid biopsy cancer diagnostics. Founded in 2012 and based in Kirkland, United States, the company was acquired by Agilent Technologies.
Pathwork Diagnostics developed molecular diagnostic tests for cancer, notably the Tissue of Origin test, which analyzes tumor gene-expression patterns to help identify the likely primary site of metastatic cancers when the origin is unknown. Its products served pathologists and oncologists managing patients with cancers of unknown primary.
Lucence is a precision oncology and health diagnostics company that provides ultrasensitive liquid biopsy tests, including cancer screening, treatment selection, and health risk assessment solutions. Using proprietary technologies like AmpliMARK, the company analyzes blood-based genetic material to detect cancer mutations, early-stage malignancies, and cardiovascular risks for patients and healthcare providers.
Predicine Holdings Ltd provides next-generation liquid biopsy platforms and molecular profiling services for cancer research and precision medicine. The company utilizes proprietary blood- and urine-based assays to analyze circulating tumor DNA and RNA, serving biopharmaceutical partners and clinical researchers in oncology drug development and clinical trials.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Capio Biosciences, Inc.? Suggest a correction · Work at Capio Biosciences, Inc.? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.